Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
published : This year tags : Vaccine save search
YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine
Published: 2024-04-18 (Crawled : 19:00) - biospace.com/
YS | $0.8 7.96% 7.38% 55K
|
n/a
|
| O: -7.45%
H: 0.0%
C: 0.0%
hepatitis vaccine license granted biopharma virus trial
Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01
Published: 2024-04-17 (Crawled : 12:00) - globenewswire.com
EVAX | $4.08 -2.63% -2.7% 25K
|
Manufacturing
|
| O: 0.25%
H: 0.0%
C: 0.0%
evx-01 first vaccine cancer trial
Pneumococcal Vaccine Market, 41% of Growth to Originate from North America, Technavio
Published: 2024-04-16 (Crawled : 22:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.12%
H: 0.51%
C: 0.51%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 1.05%
H: 0.0%
C: 0.0%
pneumococcal vaccine growth
Nature Medicine Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of “Off-the-Shelf” Neoantigen Vaccine Platform (SLATE)
Published: 2024-04-15 (Crawled : 11:00) - globenewswire.com
GRTS | $0.7459 0.05% 0.05% 2.4M
|
Health Technology
|
| O: -6.28%
H: 1.25%
C: -13.83%
vaccine results study platform
CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK
Published: 2024-04-04 (Crawled : 12:30) - biospace.com/
CVAC | $2.585 2.17% 2.13% 610K
|
Health Technology
|
| O: 2.79%
H: 2.03%
C: 0.34%
vaccine influenza collaboration program
VBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine Platform
Published: 2024-04-02 (Crawled : 14:30) - biospace.com/
VBIV | $0.591 -1.99% -2.03% 110K
|
Health Technology
| Email alert
Add to watchlist
partnership vaccine platform
Evaxion and Undisclosed Collaborator Announce Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus Aureus Infection
Published: 2024-04-02 (Crawled : 12:00) - biospace.com/
EVAX | $4.08 -2.63% -2.7% 25K
|
Manufacturing
|
| O: 6.58%
H: 14.71%
C: 14.12%
vaccine infection results
Novavax Presents Data on Updated COVID-19 Vaccine and Progress to Date on its COVID-19-Influenza Combination Vaccine Candidate at World Vaccine Congress 2024
Published: 2024-04-01 (Crawled : 12:00) - prnewswire.com
NVAX | $4.205 3.32% 3.21% 3.6M
|
Health Technology
|
| O: -1.03%
H: 0.62%
C: -3.53%
covid-19 candidate vaccine congress world
GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress
Published: 2024-03-28 (Crawled : 13:00) - globenewswire.com
GOVX | $1.57 1.29% 1.27% 32K
|
Health Technology
|
| O: 4.21%
H: 1.01%
C: 1.01%
cm04 covid-19 vaccine congress world
Moderna Advances Multiple Vaccine Programs to Late-Stage Clinical Trials
Published: 2024-03-27 (Crawled : 12:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.26%
H: 0.0%
C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 1.06%
H: 0.0%
C: 0.0%
MRNA | News S | $107.87 3.26% 3.16% 2.4M
|
Health Technology
|
| O: 2.02%
H: 1.41%
C: 0.92%
vaccine trials
Vaxart to Present at World Vaccine Congress Washington 2024 on April 3
Published: 2024-03-27 (Crawled : 12:00) - globenewswire.com
VXRT | News | $0.7422 -2.66% -2.74% 1.5M
|
Health Technology
|
| O: 0.0%
H: 7.38%
C: 5.74%
vaccine congress world
Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine
Published: 2024-03-26 (Crawled : 12:00) - biospace.com/
MRNA | News S | $107.87 3.26% 3.16% 2.4M
|
Health Technology
|
| O: 1.29%
H: 0.0%
C: -3.93%
covid-19 vaccine positive trial results
Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate
Published: 2024-03-26 (Crawled : 06:00) - globenewswire.com
DVAX | $11.75 -0.76% -0.77% 1.4M
|
Health Technology
|
| O: 0.72%
H: 0.4%
C: -1.75%
candidate vaccine valneva trial
Vaccine Market Insights Revealed in New 2024 Global Industry Report
Published: 2024-03-22 (Crawled : 16:00) - prnewswire.com
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: 0.02%
H: 0.0%
C: 0.0%
report vaccine global market
Merck Announces Positive Data on V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults
Published: 2024-03-19 (Crawled : 13:30) - biospace.com/
MRK | $126.88 -0.05% -0.13% 7.5M
|
Health Technology
|
| O: 0.0%
H: 0.68%
C: 0.63%
pneumococcal vaccine merck positive
CEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology
Published: 2024-03-19 (Crawled : 13:30) - biospace.com/
CVM | $1.47 -2.65% 0.0% 190K
|
Health Technology
|
| O: 0.0%
H: 1.46%
C: -0.98%
vaccine treat immunology
Veterinary Vaccine Global Market Forecast Report: A $19.86 Billion Market by 2033, Registering 7.3% CAGR During 2023-2033
Published: 2024-03-18 (Crawled : 19:00) - prnewswire.com
ELAN | $13.46 4.1% 0.0% 4.6M
|
Process Industries
|
| O: -0.63%
H: 0.92%
C: 0.0%
PAHC | $13.63 4.44% 4.26% 110K
|
Health Technology
|
| O: -0.16%
H: 0.8%
C: -0.08%
veterinary vaccine global market
Merck Announces Plans to Conduct Clinical Trials of a Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL®9
Published: 2024-03-13 (Crawled : 11:00) - biospace.com/
MRK | $126.88 -0.05% -0.13% 7.5M
|
Health Technology
|
| O: 0.41%
H: 0.04%
C: -0.81%
gardasil vaccine merck trials
World Vaccine Market Research Report 2023-2024 and 2030 - Increasing Consumer Awareness Towards Immunization Fueling Growth Amid Growing Prevalence of Infectious Diseases
Published: 2024-03-12 (Crawled : 02:00) - prnewswire.com
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 0.01%
H: 0.0%
C: 0.0%
report vaccine world research growing growth market
Anixa Biosciences Announces Presentation at 24th Annual World Vaccine Congress
Published: 2024-03-11 (Crawled : 17:00) - biospace.com/
ANIX | $3.06 1.66% 1.63% 73K
|
Health Technology
|
| O: -1.23%
H: 2.18%
C: 0.62%
vaccine congress world presentation
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News M | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.